n/a
Article Publish Status: FREE
Abstract Title:

Parthenolide as Cooperating Agent for Anti-Cancer Treatment of Various Malignancies.

Abstract Source:

Pharmaceuticals (Basel). 2020 Aug 14 ;13(8). Epub 2020 Aug 14. PMID: 32823992

Abstract Author(s):

Malgorzata Sztiller-Sikorska, Malgorzata Czyz

Article Affiliation:

Malgorzata Sztiller-Sikorska

Abstract:

Primary and acquired resistance of cancer to therapy is often associated with activation of nuclear factor kappa B (NF-κB). Parthenolide (PN) has been shown to inhibit NF-κB signaling and other pro-survival signaling pathways, induce apoptosis and reduce a subpopulation of cancer stem-like cells in several cancers. Multimodal therapies that include PN or its derivatives seem to be promising approaches enhancing sensitivity of cancer cells to therapy and diminishing development of resistance. A number of studies have demonstrated that several drugs with various targets and mechanisms of action can cooperate with PN to eliminate cancer cells or inhibit their proliferation. This review summarizes the current state of knowledge on PN activity and its potential utility as complementary therapy against different cancers.

Study Type : Review

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.